Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04RHJ
|
||||
Former ID |
DNCL002457
|
||||
Drug Name |
RG7116
|
||||
Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
Company |
Roche
|
||||
Target and Pathway | |||||
Target(s) | Receptor protein-tyrosine kinase erbB-3 | Target Info | Modulator | [2] | |
KEGG Pathway | ErbB signaling pathway | ||||
Calcium signaling pathway | |||||
Endocytosis | |||||
Proteoglycans in cancer | |||||
MicroRNAs in cancer | |||||
NetPath Pathway | TNFalpha Signaling Pathway | ||||
PANTHER Pathway | Cadherin signaling pathway | ||||
EGF receptor signaling pathway | |||||
Pathway Interaction Database | ErbB2/ErbB3 signaling events | ||||
ErbB receptor signaling network | |||||
a6b1 and a6b4 Integrin signaling | |||||
WikiPathways | ErbB Signaling Pathway | ||||
Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
Signaling Pathways in Glioblastoma | |||||
miR-targeted genes in muscle cell - TarBase | |||||
Heart Development | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035594) | ||||
REF 2 | RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res. 2013 Aug 15;73(16):5183-94. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.